Gynecologic Oncology

Papers
(The H4-Index of Gynecologic Oncology is 36. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Editorial board156
Physical activity and lower extremity lymphedema among endometrial cancer survivors: A population-based cross-sectional study104
Racial disparities in human papillomavirus vaccination rates and correlation with cervical cancer stage at diagnosis: A retrospective analysis87
ChatGPT vs Google: Understanding a patient's perspective on their cancer diagnosis, recommended treatment, and survival outcomes75
Endometrial stripe thickness at the time of diagnosis of uterine papillary serous carcinoma in black patients (2137)73
Prediction of ovarian cancer with deep machine-learning and alternative splicing (2167)66
The impact of bowel preparation on surgical site infection rates in gynecologic oncology surgery, post-hoc analysis from a randomized controlled trial (550)65
Short-term hormone replacement therapy in BRCA mutation carriers and risk of breast cancer: A nationwide study in Korea (1155)64
Multi-omic and clinical data analysis of pre-menopausal women under 45 years of age diagnosed with endometrial cancer and enrolled in the ASAP trial (2154)62
Adverse postoperative outcomes associated with perioperative blood transfusion in gynecologic oncology surgery: a National Surgical Quality Improvement Program analysis (467)59
The role of adjuvant radiation therapy in older patients with node-positive vulvar cancer: A national cancer database analysis58
Pattern of recurrence and survival: Comparative analysis of robotic radical hysterectomy with uterine manipulator versus without uterine manipulator and or vaginal cerclage in treatment of stage IB ce57
Ovarian and uterine carcinosarcoma cell lines show preclinical sensitivity to BAY 1895344, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor (011)55
Mitigating disparity? Recurrence rates and palliative care referrals by race and ethnicity across a large urban health system (514)55
Development of a molecular and clinical evidence-based algorithm for selecting optimal precision therapeutic strategy for patients with ovarian carcinoma (157)52
Effect of sentinel lymph node isolated tumor cells on recurrence free survival in patients with mismatch repair proficient vs. deficient stage I/II endometrioid endometrial adenocarcinoma (173)51
Role of lymphadenectomy for apparent early-stage low-grade serous ovarian carcinoma (529)51
Impact of increased cycles of neoadjuvant chemotherapy on interval debulking surgery outcomes (541)47
Improving the cancer survivorship journey: Developing a survivorship care transition model for rural and underserved low risk breast and gynecologic cancer patients (511)46
Ketogenic Diet Promotes Epithelial Ovarian Cancer Progression and Alters Tumor Gene Expression in-vivo (104)45
Highlights from the 2022 Society of Gynecologic Oncology Annual Meeting on Women's Cancer45
Impact of venous thromboembolism on timing and outcomes of interval debulking surgery among patients treated with neoadjuvant chemotherapy for advanced ovarian cancer (370)45
Molecular profiling of gestational trophoblastic neoplasia: Identifying therapeutic targets (167)43
Taking the ‘first steps’ to a healthier lifestyle: The initial acceptability and feasibility of a health behavior intervention for endometrial cancer survivors with obesity and their social support ne42
Leave it in the past: Primary treatment modality for high-grade epithelial ovarian cancer does not affect secondary cytoreduction outcomes (173)40
Food deserts, endometrial cancer survivors, and healthy food access: Is it equitable in rural America? – A geospatial analysis (2127)40
Patient-reported post-discharge opioid use after abdominal gynecologic surgery in an Enhanced Recovery After Surgery (ERAS) program (004)40
Diversifying clinical trials: Does presentation at gynecologic oncology tumor board increase equitable access to clinical trials for Black and LatinX patients? (2205)40
TOGETHER Care: PatienT-tailOred GynEcologic Oncology posT discHargE caRe (290)40
Impact of COVID-19 on gynecologic oncology patients: an SGO COVID-19 and Gynecologic Cancer Registry study (050)39
Predictors of long-term response in prospective phase II trial of levonorgestrel intrauterine device for atypical hyperplasia and early endometrial cancer (1247)39
Creation of a surgical service line to treat patients with recurrent gynecologic cancer with curative intent: Complex oncologic multidisciplinary pelvic surgery (COMPS) (559)39
Clinical impact of low-volume lymph node metastases in early- stage cervical cancer: A comprehensive meta-analysis (504)38
Prognostic factors of survival in women with recurrent platinum-resistant epithelial ovarian cancer (1171)38
Metastatic site-specific prognosis of women with stage IVB cervical cancer (345)37
Uterine cancer incidence overtakes colorectal cancer, disproportionately impacting minority women in the United States36
Perioperative outcomes after interval cytoreductive surgery and primary cytoreductive surgery for advanced epithelial ovarian cancer in Australia: A National Gynae-Oncology Registry (NGOR) study36
0.92013597488403